COVID-19
The global cellular immunotherapy market is expected to decline significantly in 2020 due to the COVID-19 pandemic, but is forecasted to recover and reach $5.05 billion in 2023 at a compound annual growth rate (CAGR) of 22.53%. The market is driven by the development of new cellular immunotherapies
Pfizer Inc.
The World Health Organization (WHO) has announced the signing of an advance purchase agreement with Pfizer-BioNTech to secure up to 40 million doses of the COVID-19 vaccine under the UN-led COVAX equitable vaccine supply programme. Additionally, 150 million doses of the AstraZeneca/Oxford vaccine are expected to be available for
Pfizer Inc.
The global cellular immunotherapy market experienced a decline in 2020 due to the COVID-19 pandemic, with a CAGR of -5.90% and a revenue of $2.74 billion. However, the market is expected to recover and reach $5.05 billion in 2023, with a CAGR of 22.53%. The market
Pharmaceutical industry
The global biosimilar therapeutic peptides market is facing a decline due to the COVID-19 pandemic, with a compound annual growth rate (CAGR) of -3.45% expected in 2020. The market, which was valued at $0.80 billion in 2019, is projected to recover and reach $1.72 billion in 2023
Pharmaceutical industry
Maine's state health officials recently intervened to redirect approximately 1,950 unused COVID-19 vaccine doses from Walgreens to two Lewiston hospitals, Central Maine Medical Center and St. Mary's Regional Medical Center. This decision was made after state officials discovered that Walgreens had not scheduled vaccinations for
COVID-19
As President-elect Joe Biden prepared to take office amidst the ongoing coronavirus pandemic, he reinforced his administration's commitment to vaccination by receiving the second dose of the Pfizer/BioNTech Covid-19 vaccine on Monday. This public display of vaccination serves as a reassurance to the American public, who have
COVID-19
As Ontario continues to struggle with high COVID-19 case counts and the emergence of new, more transmissible variants, concerns are growing over the prioritization of vaccine distribution. Some Toronto hospitals have started vaccinating non-frontline staff, including executives, raising questions about the ethics of immunizing these employees ahead of community health
Pfizer Inc.
The US Food and Drug Administration (FDA) has confirmed that it does not plan to make any changes to Covid-19 vaccine dosing schedules in the United States, citing the lack of evidence and potential risks associated with altering the recommended dosing. This stance has been reinforced by health officials, including
Pfizer Inc.
A California nurse has tested positive for Covid-19 nearly a week after receiving Pfizer Inc's vaccine, underscoring the complex and evolving nature of vaccine efficacy. Matthew W, a 45-year-old nurse who works at two hospitals, received the Pfizer vaccine and fell ill six days later, despite experiencing only
Pfizer Inc.
California Governor Gavin Newsom announced the state's participation in the federal COVID-19 Pharmacy Partnership, which will enable CVS and Walgreens to administer the Pfizer vaccine to residents and staff in long-term care facilities at no cost to the state or local government. The partnership aims to prioritize the
Pfizer Inc.
California has joined the federal COVID-19 Pharmacy Partnership, a program that will provide no-cost Pfizer vaccines to residents and staff in long-term care facilities. The partnership, led by CVS and Walgreens, aims to vaccinate those most vulnerable to the virus, leveraging the pharmacies' resources to effectively deploy vaccines to
Pfizer Inc.
The arthritis monoclonal antibodies market is experiencing a decline in growth due to the COVID-19 pandemic, but it is expected to recover and reach $56.05 billion in 2023. The market was valued at $46.48 billion in 2019 and is expected to decline to $45.18 billion in 2020
